Inhibition by acycloguanosine (ACG) of plaque formation by herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus, and cytomegalovirus was studied. Seventeen clinical isolates of HSV-1 were inhibited by ACG at a mean 50% inhibitory dose (ID5o) of 0.15 ± 0.09 AM. The mean ID50 for 10 isolates of HSV-2 was 1.62 ± 0.76 pM, and for four isolates of varicella-zoster virus it was 3.75 ± 1.30 uM. The ID50's for two cytomegalovirus isolates were 100 and 160 ,uM, and for four additional isolates of cytomegalovirus no end point (ID50) was reached at 200 pM. ACG at a concentration of 200 ,uM had no effect on deoxyribonucleic acid synthesis in human fibroblast cells and only inhibited thymidine incorporation by Vero cells by one-third. These studies demonstrated the antiviral activity of ACG against clinical isolates of HSV-1, HSV-2, and varicella-zoster virus and the lack of toxicity to monkey or human cells in culture at concentrations which markedly inhibited these viruses. ACG had little effect on cytomegalovirus at concentrations in excess of 100 uM.
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The human herpesviruses cause a wide spectrum of acute and recurrent diseases which vary in severity from mild to life threatening (4, 6, 8, 17, 25) . Although a large number of agents have been investigated, only two of these, adenine arabinoside and interferon, have been shown in clinical trials to favorably alter the course of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections (1, 13, 15, 23, 24) . Nevertheless, severe sequelae and treatment failures do occur in spite of the use of these agents, and attempts to treat visceral involvement by increasing the dose are likely to be complicated by myelo-and immunosuppressive side effects (2, 5, 10, 11, 22, 24) . A new antiviral agent, acycloguanosine [ACG; 9-(2-hydroxyethoxymethyl) guanine], is active against human herpesviruses, both in vitro and in animals infected with HSV (7, 20) . ACG requires a virus-specific thymidine kinase for conversion to ACG-triphosphate, an inhibitor of viral deoxyribonucleic acid (DNA) polymerase (7) . This property makes the compound very selective for virus-infected cells, and ACG has a high in vitro therapeutic ratio. The available information on the susceptibility of herpesviruses to ACG is limited and is primarily derived from the testing of laboratory strains. In this report the susceptibilities of isolates from human infections with HSV, VZV, and cytomegalovirus (CMV) to ACG are described.
MATERIALS AND METHODS Cells. Primary rabbit kidney cell cultures were prepared by a multiple extraction method (4) . A cell strain of human foreskin fibroblasts (350 Q) derived by M. Myers was used at passages 17 to 22 (21) . These cell cultures were maintained in Dulbecco modified Eagle medium supplemented with 2% fetal calf serum and antibiotics (penicillin, 250 U/ml; streptomycin, 250 Ag/ml). The Vero line of African green monkey kidney cells was obtained from Microbiological Associates (Bethesda, Md.) and maintained in medium 199 containing 2% fetal calf serum and antibiotics. Cell lines were free of mycoplasmas when tested on Hayflick medium.
Viruses. (i) HSV-1. HSV type 1 (HSV-1) isolates were obtained from patients with recurrent facial-oral herpes labialis. Virus was isolated in primary rabbit kidney cell cultures, and a pool was prepared by lowmultiplicity passage in Vero cells. Pools were harvested and frozen at -70°C when the cell sheet showed complete cytopathic effect.
(ii) HSV-2. HSV-2 isolates were obtained from patients with herpes progenitalis or neonatal herpes infection, and pools were prepared as described above. HSV isolates were identified as HSV-1 or HSV-2 by a simplified microneutralization technique (21) .
(iii) VZV. Clinical isolates of VZV were obtained from patients with varicella or herpes zoster. VZV was isolated, and a pool was prepared in human fibroblasts.
A laboratory strain (CP 5262; Center for Disease Control, Atlanta, Ga.) was also studied. Cell-free VZV was prepared by scraping the cell sheet once when cytopathic effect occurred in 50% of cells, sonic treatment on June 17, 2017 by guest http://aac.asm.org/ Downloaded from (model no. W185; Heat Systems-Ultrasonics, Inc., Plainview, N.Y.; 60 W, 10), clarification (600 x g, 10 min), and storing the supernatant at -70°C in sorbitol (7% final concentration). Cell-associated virus was prepared by trypsinization and stored at -700C at a concentration of 106 cells per ml in medium containing 8% dimethyl sulfoxide and 30% serum. VZV was identified by typical cytopathic effect growth characteristics, and the histological appearance of fixed slides.
(iv) CMV. CMV isolates were obtained from bone marrow transplant recipients with febrile illnesses or from normal individuals with a CMV mononucleosis syndrome. Cell-free and cell-associated virus pools were prepared as described for VZV from virus grown on 350 Q cells. Two laboratory strains (Davis and AD 169) were also studied. CMV was identified by growth characteristics and fluorescent-antibody staining of infected cultures (12) .
All virus pools were titered by plaque titration on Vero (HSV-1 and HSV-2) or 350 Q (VZV and CMV) cells, using methyl cellulose overlay (4).
Drugs. ACG (BW 248U) was supplied by the Burroughs Wellcome Co. To determine anti-HSV activity, monolayers of Vero cells (seeded with 3 x 105 cells in 3 ml) were prepared in 6-well (35 mm) plastic tissue culture plates (Linbro Div., Flow Laboratories, Inc., Rockville, Md.). Three days later, confluent monolayers were inoculated with approximately 100 plaque-forming units in 0.2 ml of medium containing ACG. After 1 h at 37°C, the inoculum was removed and 3 ml of 1% methyl cellulose was added. Methyl cellulose was prepared in medium containing 2% serum and appropriate concentrations of ACG. After 5 days at 37°C in 10% C02-90% air, the monolayers were fixed with acetic acid-methanol (1: 3) and stained with 1% crystal violet, and the plaques were counted. The amount of ACG required to reduce plaques by 50% (ID5o) from the number present in the control wells without drug was calculated directly from the nonlinear plot relating surviving plaques in the presence of increasing concentrations of ACG in the medium. No attempt was made to obtain linearity.
(ii) VZV. The ID50 of VZV was determined by a similar technique, using 4-day-old confluent monolayers of 350 Q cells (seeded with 6 x 105 cells in 3 ml). After 4 days of incubation, the infected cells were fixed with 10% Formalin, the methyl cellulose was removed, and the plates were washed with water. The monolayers were stained with 0.03% methylene blue, and the plaques were counted.
(iii) CMV. The ID50 of CMV was determined as above, using 4-day-old confluent monolayers of 350 Q cells in 24-well cluster tissue culture plates (Costar, Data Packaging, Cambridge, Mass. (Fig. 1) . Six isolates of CMV were resistant to ACG; four failed to show 50% plaque reduction at 200 ,uM, and two isolates had ID50's of 100 and 160 jiM.
Typical kinetics of plaque reduction by ACG for each of the human herpesviruses tested are shown in Fig. 2 . These curves (Fig. 2) show the result of single determinations on single isolates. Similar kinetics were obtained in multiple determinations on all of the isolates. Only for CMV was there persistence of plaques at a concentration of ACG greater than 10 ,uM. Cell-free and cell-associated VZV were inhibited with similar kinetics (data not shown).
DNA synthesis by the mammalian cells used for the assay of antiviral effect was determined in the presence of ACG (Table 1) Both the Vero cells and the human fibroblast cells were viable and continued to increase in number daily when counted for 7 days after the addition of ACG to the media. Thus, the ACG did not appear to have a delayed effect on host cell DNA synthesis which would not be detected during an 18-h exposure to [3H] thymidine. This method of assaying for cell cytotoxicity only looks at the effects ofthe drug on DNA synthesis and does not assess possible inhibition of protein or ribonucleic acid synthesis. DNA synthesis appeared to be the most sensitive parameter of macromolecular synthesis to examine, as ACG is a nucleoside analog whose primary effects have been shown to be on viral DNA synthesis (7) . DISCUSSION Schaeffer et al. showed that ACG inhibited the ICI laboratory strain of HSV-1 at an ID5o of 0.10 uM (20) . Three other laboratory strains (KOS, McIntyre, and H29) have been used in studies on the drug, but their ID5o's were not reported (7) . We find that all HSV-1 isolates from human disease are similarly susceptible (mean ID5o = 0.15 AM). Their inhibitory range of 0.06 to 0.35 ,uM indicates that naturally occurring resistance to ACG by HSV-1 is uncommon. The mean ID50 for 10 strains of HSV-2 was 1.62 ,AM, a value 10-fold higher than the value of 0.14 AM reported by Schaeffer et al. (20) . Both studies were carried out by plaque reduction in Vero cells. Part of the discrepancy is explained by the range of susceptibility of the isolates we studied. Although HSV-2 is less susceptibie to ACG, it is still inhibited by levels readily attained in human serum during parenteral administration (R. E. Keeney, personal commnunication). The greater susceptibility to ACG of HSV-1, compared with HSV-2, resembles the relative susceptibility observed with other antiviral compounds, such as 5, 6-dihydro-5-azathymidine (19) and adenine arabinoside (14) . Although it has been stated that VZV and CMV are inhibited by ACG (20) , the data have not been published. We observed that clinical isolates of VZV are readily inhibited by clinically attainable levels of ACG and that cell-free and cell-associated viruses are equally susceptible. Studies on CMV isolates indicate that the ID5o's for four isolates are greater than 200 tM and that the ID5o's for two others are 100 and 160
AM.
The exact reason why CMV is not susceptible to ACG at the noncytotoxic concentrations used is not apparent. The fact that CMV is not known to induce a virus-coded thymidine kinase suggests that CMV-infected cells do not convert ACG to the active form, ACG-triphosphate, and thus viral DNA replication is not inhibited. In HSV-infected cells, ACG-triphosphate has been shown to be a noncompetitive inhibitor of virusinduced DNA nucleotidyltransferase (7) . These results might be further evidence that CMV does not require its own thyniidine kinase for replication, that it utilizes a cell thymidine kinase which does not convert ACG to an active inhibitor, or that it replicates without any requirement for thymidine kinase at all. An alternative explanation is that the CMV-induced DNA nucleotidyltransferase is very resistant to the action of ACG-triphosphate.
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